PAR - Deal me in, page-83

Hey Mozz - Amgen just announced a takeover of a phase 3 ready bio on the oncology field. One of the reasons stated for the takeover was to maintain a lead in Oncology field.

Upon further reading, Amgen's blockbuster drug is Enbrel - have you written about Enbrel before? it's a RA drug and I just wonder if an OA drug may just fit the portfolio of a company like Amgen...perhaps compliments their RA offering. Regardless, Enbrel just might provide some insight to the pathway Zilosul could potentially take one day - in terms of cost to patient and revenues it could generate.